Inventor
STEPHEN M. CONDON
Inventor
US
Overview
Patents· 10 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Pprimary
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations23%
A61KPreparations for medical, dental or toiletry purposes19%
C07DHeterocyclic compounds16%
C07FAcyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium16%
A61NElectrotherapy5%
C07HSugars5%
C07KPeptides5%
C12NMicroorganisms or enzymes5%
Y02PClimate change mitigation technologies in the production or processing of goods5%
C07CAcyclic or carbocyclic compounds2%
PatentTitleYear
12,544,395Combination compositions comprising a beta-lactamase inhibitor and uses thereof202612,173,018Penicillin-binding protein inhibitors202412,102,648Orally-bioavailable nucleoside analogs202412,084,445Broad-spectrum carbapenems202411,951,147SMAC mimetic202411,638,715Orally-bioavailable nucleoside analogs202311,566,001Hepatitis B capsid assembly modulators202311,351,221SMAC mimetic202211,332,485Penicillin-binding protein inhibitors202211,247,965Hepatitis B capsid assembly modulators2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2026Patents assigned to VENATORX PHARMACEUTICALS INC (8)· patent assignee history
2022–2024Patents assigned to MEDIVIR AB (2)· patent assignee history
2022–2026Based in US· patent location history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| VENATORX PHARMACEUTICALS INC | 8 | 2022–2026 |
| MEDIVIR AB | 2 | 2022–2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 10 | 2022–2026 |